General Information of Drug (ID: DM0ZDJ5)

Drug Name
Anti-EGFL7 Drug Info
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM0ZDJ5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MEGF0444A DM2C1YN Metastatic colorectal cancer 2B91 Phase 2 [3]
RG7414 DMCQRS2 Colorectal cancer 2B91.Z Discontinued in Phase 2 [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Epidermal growth factor-like protein 7 (EGFL7) TT7WD0H EGFL7_HUMAN Not Available [2]

References

1 Clinical pipeline report, company report or official report of Genentech (2011).
2 Clinical pipeline report, company report or official report of Genentech (2009).
3 A first-in-human phase Ia open-label dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) administered intravenously in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts) May 2011 vol.29 no.15_suppl 2614.
4 Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest. 2013 September 3; 123(9): 3997-4009.